ALNY News and Press, Alnylam Pharmaceuticals Inc. From 09/13/22

Alnylam ( NASDAQ: ALNY ) has priced its previously announced private offering of $900M principal amount of 1.00% convertible senior notes due 2027. The initial purchasers are granted an option to purchase an additional $135.0M aggregate principal amount of the notes. ...

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) shares dropped over 5% on Monday after the RNAi therapeutics company proposed an offering of $900M convertible senior notes due 2027. The notes will accrue interest payable semi-annually in arrears and will mature on Sep 15, 2027,...

The shares of Alnylam Pharmaceuticals, Inc. ( NASDAQ: ALNY ), a biotech focused on RNAi therapeutics, trended lower in the pre-market trading Monday after the company announced the start of a private offering of $900M of senior convertible notes due 2027. The initial purch...

Summary Today, we revisit Arbutus Biopharma Corporation for the first time in almost a year. An interesting 'sum of the parts' story seems to be emerging around the company and the stock. An investment analysis follows in the paragraphs below. "I could easily for...

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to pers...

RNAi therapeutics company Alnylam Pharmaceuticals ( NASDAQ: ALNY ) announced full results from its APOLLO-B Phase 3 study of patisiran, an investigational medication for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The 12-month trial involving 360 adult pat...

– Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyopathy of ATTR Amyloidosis – – Patisiran met Primary Endpoint, Demonstrating Significant Clinical Benefit o...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When my son was younger, he was obsessed with rockets. In fact, we have a seven-foot rocket still in my Florida garage. What I learned during his rocket phase was that if you make a rocket bigger, especially a liquid-fueled...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 11:10 am ET at the Sheraton New ...